OXCT1

Across TCGA pan-cancer cohorts, OXCT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of OXCT1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where OXCT1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types OXCT1 is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where OXCT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in OXCT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	−0.855	<.001	12	view →
CCRCC	Male	III,IV	−1.126	<.001	11	view →
COAD	Male	III,IV	−1.024	<.001	11	view →
LSCC	Female	II,III,IV	+0.680	<.001	8	view →
LUAD	All	II,III,IV	+0.290	.004	5	view →
PDAC	All	II,III,IV	−0.270	.004	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

OXCT1–HNSC

Open the HNSC breakdown →